FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787061857> ?p ?o ?g. }

• W2787061857 endingPage "41" @default.
• W2787061857 startingPage "39" @default.
• W2787061857 abstract "AIDS Patient Care and STDsVol. 32, No. 2 Letter to the EditorOpen AccessLinkage and Antiretroviral Therapy Within 72 Hours at a Federally Qualified Health Center in New OrleansJason Halperin, Isolde Butler, Katherine Conner, Leann Myers, Pamela Holm, Logan Bartram, and Nicholas Van SickelsJason HalperinCrescentCare, New Orleans, Louisiana.Search for more papers by this author, Isolde ButlerCrescentCare, New Orleans, Louisiana.Search for more papers by this author, Katherine ConnerCrescentCare, New Orleans, Louisiana.Search for more papers by this author, Leann MyersGlobal Biostatistics and Data Science, School of Public Health and Tropical Medicine, Tulane University New Orleans, New Orleans, Louisiana.Search for more papers by this author, Pamela HolmCrescentCare, New Orleans, Louisiana.Search for more papers by this author, Logan BartramDepartment of Internal Medicine, Tulane University School of Medicine, New Orleans, Louisiana.Search for more papers by this author, and Nicholas Van SickelsCrescentCare, New Orleans, Louisiana.Search for more papers by this authorPublished Online:1 Feb 2018https://doi.org/10.1089/apc.2017.0309AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail While HIV incidence declines nationally, the Southern United States remains disproportionally affected. New Orleans ranks third in the United States for the rate of new HIV infections.1 Previous studies in San Francisco, Haiti, and South Africa have shown that immediate initiation of antiretroviral therapy (ART) leads to earlier virologic suppression, increased retention in care, and decreased mortality.2–4 Further, the publication of three influential studies showed no linked transmission events in patients when ART results in viral suppression.5 Scientific advances demonstrate that effective treatment with ART prevents sexual HIV transmission.6 The Centers for Disease Control and Prevention has endorsed the concept of U = U (undetectable = untransmittable.)7The Federally Qualified Health Center (FQHC), CrescentCare, partnered with the New Orleans Office of Health Policy, to start all newly diagnosed patients on ART within 72 h of diagnosis. The CrescentCare Start Initiative (CCSI) enhances navigation, expedites clinic intake, and initiates immediate ART. CCSI started on December 1, 2016, and in October 2017 underwent an analysis comparing the first 8 months to a matched cohort.A Standard Operating Procedure (SOP) was disseminated agency wide, including training sessions for all providers. CCSI optimized provider availability and the navigator scheduled patients into any available slot. The intervention leveraged existing CrecentCare-run HIV testing sites, its sexually transmitted diseases (STD) clinic, and informed the clinic's referral network. A navigator was available 24 h per day to coordinate linkage of new diagnoses. The intake process for CCSI was streamlined for a focused HIV visit with a treating provider. Initial visit was 30 min. The first dose of ART was directly observed. Providers were encouraged to use tenofovir alafenanide/entricitabine (TAF/FTC) + dolutegravir as the initial regimen. It was chosen for the regimen's effectiveness, tolerability, and empiric coverage of hepatitis B, and approved use in patients with a creatinine clearance greater than or equal to 30 mL/min. After the visit, baseline HIV labs were drawn, and patients saw case management, behavioral health, and eligibility specialists when indicated.A medical checklist was developed to standardize workflow. All primary-care providers committed to seeing patients for the initial visit. Referral was then made to an HIV specialist for on-going management. Labs were reviewed within 48 h. An HIV specialist regularly reviewed patient encounters. Follow-up appointments were made within 4 weeks and were longer in duration. The patient navigator assisted with all appointments through the second provider visit. The provider or patient could decline therapy through shared decision making.In October, CCSI was compared to a cohort from the previous year. The comparator group tested positive at CrescentCare community testing sites and used the same navigator to minimize confounders. The 29 patients in the cohort saw an HIV specialist for their initial visit and were started on an integrase-based initial regimen (Table 1).Table 1. Demographics CCSI (n = 71), n (%)Historical cohort (n = 29), n (%)Male51 (71.8)27 (93.1)Transgender2 (2.8)2 (6.9)African American38 (52.8)19 (65.5)Latino7 (9.9)2 (6.9)MSM39 (54.9)24 (82.8)Heterosexual28 (39.4)5 (17.2)People who inject drugs3 (4.2)7 (24.1)Uninsured at baseline38 (53.5)18 (62.1)Syphilis15 (21.1)8 (27.6)GC/CT22 (31)11 (37.9)Hep C4 (5.7)0 (0)Homeless5 (7.3)1 (3.5)Tobacco use24 (34.3)15 (51.7)Drug use other than THC16 (22.4)6 (20.7)Age (mean + SD)31.1 + 10.532.3 + 10.4Baseline CD4 count (median)419 cells/mm3408 cells/mm3Baseline viral load (median)41,900 copies/mL36,130 copies/mLThere were significant differences between gender, sexual orientation, and intravenous drug use between the two groups.CCSI, CrescentCare Start Initiative; GC/CT, gonorrhea/chlamydia; MSM, men who have sex with men; THC, marijuana.Viral suppression was defined as an HIV RNA less than 200 copies/mm3. Time to suppression was defined as days from diagnosis to viral suppression. All patient information and data points were complete through October 6, 2017. For patients who transferred care, the last viral load was used for analysis. Continuous characteristics were compared using Wilcoxon's rank-sum test, given that normality could not be assumed. HIV viral load was log-transformed before analysis. Pearson's χ2 test was used to compare categorical variables (Fisher's exact test when sample size assumptions were not met). Time to suppression (median and 95% confidence interval) was estimated using the Kaplan-Meier product-limit method; the logrank test was used to assess differences in time to suppression between the two groups of patients. Analyses were conducted using SAS software v. 9.4 (SAS Institute, Inc., Cary, NC).Seventy-seven patients with a new diagnosis of HIV were referred to CCSI from December 5, 2016, to August 6, 2017. 92% (71/77) were linked, saw a treating provider, and started ART within 72 h of diagnosis. Four of the six patients not linked within 72 h were linked to care within 30 days of diagnosis. 69% (49/71) were seen within 24 h of diagnosis, and the remainder (31%, 22/71) within 72 h. Tenofovir alafenamide/emtricitabine + dolutegravir was started in 69 patients. Two patients received an alternate regimen, one with end-stage renal disease and another who seroconverted on PrEP. All 71 patients were started on ART and had their first dose directly observed.CCSI was compared to a cohort of 29 patients diagnosed and linked between December 2015 and August 2016. The mean time to linkage in the historical cohort was 30 days (95% CI: 25.1–43.6 days) compared to 1.3 days (95% CI: 1.09–1.51 days) in CCSI (p < 0.0001). The median time to viral suppression (<200 copies/mm3) in the historical cohort was 68 days (95% CI: 60–92 days) compared to 30 days (95% CI: 27–34 days) in CCSI (p < 0.0001). There were no significant differences between the groups by baseline viral load, CD4 count, or ART regimen (Fig. 1).FIG. 1. The relationship between% virally suppressed (<200 copies/mL) and time to viral suppression among patients newly diagnosed with HIV infection as part of the CCSI compared to historical cohort. This Kaplan–Meier plot shows the proportion of patients with viral load <200 copies/mL HIV RNA over time. Time to viral suppression for patients in the CrescentCare Start Initiative was a median of 30 days (blue line) and significantly shorter than for patients treated in the historical cohort for 68 days (red line). CCSI, CrescentCare Start Initiative. (Color image can be found at www.liebertonline.com/apc).23% (14/61) of CCSI patients had transmitted resistance. Two had NRTI resistance with the M184V/I mutation and 12 had NNRTI resistance. All patients with transmitted resistance achieved viral suppression. Ten genotypes failed or were not performed at baseline. All 71 CCSI patients achieved viral suppression. By the end of the study period, viral suppression was maintained in 70 of 71 patients [median 135 days, interquartile range (IQR) = 117; Q1 = 90, Q3 = 207]; one patient had rebound viremia due to nonadherence.CrescentCare has witnessed a significant increase in referrals to the clinic following implementation. At the time of article drafting, 112 patients have accessed immediate treatment. The successes of this intervention include high rates of linkage to care, earlier viral suppression, and sustained impact over time. A full-time navigation specialist was essential for patient engagement. The use of an SOP and medical checklist ensured that non-HIV specialists could provide this model of care. This model is dependent on same-day accessibility. The FQHC structure with guaranteed same-day appointments, extended hours, and wrap-around services lends itself very well to an immediate start initiative.Previous studies have shown poorer health outcomes when HIV care is provided by clinicians with lower HIV caseloads.8 This intervention, due to the requirement of immediate accessibility, incorporated a potential first appointment with a generalist to initiate ART and then referral to a specialist. Patients were seen, triaged, and treated effectively, but further analysis of long-term outcomes is necessary.The limitations of this study are that it was nonrandomized and the control used for analysis was historical. There were significant differences between the two groups, including gender, sexual orientation, and intravenous drug use (IVDU). Of these, IVDU has been shown to decrease rates of viral suppression9 and could have impacted this comparison. Further scaling up of this intervention will require targeted resources to invest in patient navigation, immediate patient access, and coverage for the cost of the first 30 days of medication.The success of this intervention depends on its sustainability, future retention-in-care outcomes, and continued viral suppression. To reach the 2020 United Nations goal of 90/90/90,10 the impact must be sustained. The HIV epidemic in the Southern United States requires urgent and novel interventions. Rapid access to therapy improves health outcomes and renders our patients uninfectious. Immediate initiation of ART can be effectively provided in a community FQHC and play a significant role in ending the HIV epidemic.AcknowledgmentsDr. L.M. was supported, in part, by U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center.Author Disclosure StatementNo competing financial interests exist.References1 Singh S, Song R, Johnson A, et al. (CDC). HIV Incidence, Prevalence, and Undiagnosed Infections in Men Who Have Sex with Men. Presented at: Conference on Retroviruses and Opportunistic Infections, 2017, Seattle, WA. Google Scholar2 Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr 2017;74:44–51. Crossref, Medline, Google Scholar3 Koenig SP, Dorvil N, De vieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med 2017;14:e1002357. Crossref, Medline, Google Scholar4 Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: The RapIT randomized controlled trial. PLoS Med 2016;13:e1002015. Crossref, Medline, Google Scholar5 Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016;316:171–181. Crossref, Medline, Google Scholar6 U = U taking off in 2017. Lancet HIV 2017;4:e475. Crossref, Medline, Google Scholar7 McCray E, Mermin J. Dear colleague: September 27, 2017. 2017. Available at: www.cdc.gov/hiv/library/dcl/dcl/092717.html (Last accessed November 5, 2017). Google Scholar8 Landovitz RJ, Desmond KA, Gildner JL. Quality of care for HIV/AIDS and for primary prevention by HIV specialists and nonspecialists. AIDS Patient Care STDS 2016;30:395–408. Link, Google Scholar9 Westergaard RP, Hess T, Astemborski J, et al. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS 2013;27:2559–2566. Crossref, Medline, Google Scholar10 Corless IB, Hoyt AJ, Tyer-Viola , et al. 90-90-90-Plus: Maintaining adherence to antiretroviral therapies. AIDS Patient Care STDS 2017;31:227–236. Link, Google ScholarFiguresReferencesRelatedDetails Volume 32Issue 2Feb 2018 Information© Jason Halperin, et al.,To cite this article:Jason Halperin, Isolde Butler, Katherine Conner, Leann Myers, Pamela Holm, Logan Bartram, and Nicholas Van Sickels.Linkage and Antiretroviral Therapy Within 72 Hours at a Federally Qualified Health Center in New Orleans.AIDS Patient Care and STDs.Feb 2018.39-41.http://doi.org/10.1089/apc.2017.0309creative commons licensePublished in Volume: 32 Issue 2: February 1, 2018PDF download" @default.
• W2787061857 created "2018-02-23" @default.
• W2787061857 creator A5007800156 @default.
• W2787061857 creator A5020033096 @default.
• W2787061857 creator A5037106578 @default.
• W2787061857 creator A5043305386 @default.
• W2787061857 creator A5048402682 @default.
• W2787061857 creator A5087743666 @default.
• W2787061857 creator A5088273555 @default.
• W2787061857 date "2018-02-01" @default.
• W2787061857 modified "2023-09-27" @default.
• W2787061857 title "Linkage and Antiretroviral Therapy Within 72 Hours at a Federally Qualified Health Center in New Orleans" @default.
• W2787061857 cites W2002681770 @default.
• W2787061857 cites W2363480212 @default.
• W2787061857 cites W2461009619 @default.
• W2787061857 cites W2496900837 @default.
• W2787061857 cites W2518861092 @default.
• W2787061857 cites W2616617093 @default.
• W2787061857 cites W2737303094 @default.
• W2787061857 cites W4232747445 @default.
• W2787061857 doi "https://doi.org/10.1089/apc.2017.0309" @default.
• W2787061857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5808385" @default.
• W2787061857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29432044" @default.
• W2787061857 hasPublicationYear "2018" @default.
• W2787061857 type Work @default.
• W2787061857 sameAs 2787061857 @default.
• W2787061857 citedByCount "24" @default.
• W2787061857 countsByYear W27870618572018 @default.
• W2787061857 countsByYear W27870618572019 @default.
• W2787061857 countsByYear W27870618572020 @default.
• W2787061857 countsByYear W27870618572021 @default.
• W2787061857 countsByYear W27870618572022 @default.
• W2787061857 countsByYear W27870618572023 @default.
• W2787061857 crossrefType "journal-article" @default.
• W2787061857 hasAuthorship W2787061857A5007800156 @default.
• W2787061857 hasAuthorship W2787061857A5020033096 @default.
• W2787061857 hasAuthorship W2787061857A5037106578 @default.
• W2787061857 hasAuthorship W2787061857A5043305386 @default.
• W2787061857 hasAuthorship W2787061857A5048402682 @default.
• W2787061857 hasAuthorship W2787061857A5087743666 @default.
• W2787061857 hasAuthorship W2787061857A5088273555 @default.
• W2787061857 hasBestOaLocation W27870618571 @default.
• W2787061857 hasConcept C104317684 @default.
• W2787061857 hasConcept C142462285 @default.
• W2787061857 hasConcept C185592680 @default.
• W2787061857 hasConcept C2779463800 @default.
• W2787061857 hasConcept C2993143319 @default.
• W2787061857 hasConcept C3013748606 @default.
• W2787061857 hasConcept C31266012 @default.
• W2787061857 hasConcept C512399662 @default.
• W2787061857 hasConcept C54355233 @default.
• W2787061857 hasConcept C71924100 @default.
• W2787061857 hasConcept C8010536 @default.
• W2787061857 hasConcept C86803240 @default.
• W2787061857 hasConceptScore W2787061857C104317684 @default.
• W2787061857 hasConceptScore W2787061857C142462285 @default.
• W2787061857 hasConceptScore W2787061857C185592680 @default.
• W2787061857 hasConceptScore W2787061857C2779463800 @default.
• W2787061857 hasConceptScore W2787061857C2993143319 @default.
• W2787061857 hasConceptScore W2787061857C3013748606 @default.
• W2787061857 hasConceptScore W2787061857C31266012 @default.
• W2787061857 hasConceptScore W2787061857C512399662 @default.
• W2787061857 hasConceptScore W2787061857C54355233 @default.
• W2787061857 hasConceptScore W2787061857C71924100 @default.
• W2787061857 hasConceptScore W2787061857C8010536 @default.
• W2787061857 hasConceptScore W2787061857C86803240 @default.
• W2787061857 hasIssue "2" @default.
• W2787061857 hasLocation W27870618571 @default.
• W2787061857 hasLocation W27870618572 @default.
• W2787061857 hasLocation W27870618573 @default.
• W2787061857 hasLocation W27870618574 @default.
• W2787061857 hasOpenAccess W2787061857 @default.
• W2787061857 hasPrimaryLocation W27870618571 @default.
• W2787061857 hasRelatedWork W1973460911 @default.
• W2787061857 hasRelatedWork W2096903645 @default.
• W2787061857 hasRelatedWork W2115165681 @default.
• W2787061857 hasRelatedWork W2520411286 @default.
• W2787061857 hasRelatedWork W2887187324 @default.
• W2787061857 hasRelatedWork W2915885685 @default.
• W2787061857 hasRelatedWork W4322484426 @default.
• W2787061857 hasRelatedWork W4381740084 @default.
• W2787061857 hasRelatedWork W148066406 @default.
• W2787061857 hasRelatedWork W2522518582 @default.
• W2787061857 hasVolume "32" @default.
• W2787061857 isParatext "false" @default.
• W2787061857 isRetracted "false" @default.
• W2787061857 magId "2787061857" @default.
• W2787061857 workType "article" @default.